Could a cancer drug tame rare clotting disorder?

NCT ID NCT05671757

Recruiting now Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether daratumumab, a drug used for certain cancers, is safe for people with antiphospholipid syndrome (APS), an autoimmune disorder that raises blood clot risk. Up to 22 adults will receive weekly infusions for 8 weeks at different doses. The main goal is to check for serious side effects during dose escalation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: daratumumab (a drug that targets immune cells)
What this could lead to: If safe and effective, daratumumab could offer a new treatment option for antiphospholipid syndrome, reducing blood clot risk.
What could go wrong: This is a very early, small safety trial (phase 1b/2) with only 22 participants. It may not show benefit, and side effects like infections or allergic reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

antiphospholipid syndrome autoimmune disease primary antiphospholipid syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISORDERS

Contacts and locations

Locations

Duke University
RECRUITING

Durham, North Carolina, 27710, United States
Hospital for Special Surgery
RECRUITING

New York, New York, 10021, United States
Johns Hopkins University
RECRUITING

Baltimore, Maryland, 21205, United States
Mayo Clinic Rochester
COMPLETED

Rochester, Minnesota, 55905, United States
NYU Langone
RECRUITING

New York, New York, 10016, United States
Northwell Health
RECRUITING

Great Neck, New York, 11021, United States
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States
Weill Cornell
RECRUITING

New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.